Drug Targeting and Delivery Systems for Breast Cancer Treatment
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 198
Special Issue Editors
Interests: systems biology; tumor reversion; space biomedicine; breast cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Breast cancer is one of the most common tumors in women, and is also one of the leading causes of death. The pathogenesis recognizes a multifactorial pattern, and thus acts differently during the specific stages through which cancer progresses: local development, lymph node metastasis, and the spread over tissues and distal organs (bones, lungs, lenses, and brain). Early diagnosis is critical, since an aggressive neoplastic form is observed in 10-15% of patients, triggering metastasis development within 3 or 10 years.
From a clinical point of view, breast cancer is a fibrotic tumor that is strongly influenced, in terms of its growth and therapeutic response, by interactions with highly heterogenic stromal cell subsets and extracellular matrix components. On the other hand, recent advances in cellular and molecular profiling have dramatically increased our knowledge of cancer biology and opened up a variety of novel approaches that may defeat heterogeneous diseases in precision medicine. Breast cancer heterogeneity implies the need for personalized therapeutic approaches in order to fully characterize and investigate its pathogenetic profile; this is so that novel diagnostic tools, targeted therapies, and drug delivery systems can be developed.
The scope of this Special Issue is to provide knowledge on recent advances through a series of high-quality, multidisciplinary research articles that describe all aspects of new therapeutic strategies in the field of breast cancer treatment. Potential topics include, but are not limited to, the following: the characterization of the tumor microenvironment, targeting of novel biomarkers or cell subsets, drug repurposing, the basis of therapeutic resistance, target therapy, and drug delivery systems for breast cancer treatment. We welcome original research and review articles.
Dr. Mariano Bizzarri
Dr. Mirko Minini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug delivery
- breast cancer
- target therapy
- nanoparticles
- liposomes
- microfluidics
- organoids
